Literature DB >> 32903060

PI-RADS Versions 2 and 2.1: Interobserver Agreement and Diagnostic Performance in Peripheral and Transition Zone Lesions Among Six Radiologists.

Rajesh Bhayana1, Aileen O'Shea1, Mark A Anderson1, William R Bradley1, Ravi V Gottumukkala1, Amirkasra Mojtahed1, Theodore T Pierce1, Mukesh Harisinghani1.   

Abstract

BACKGROUND. PI-RADS version 2.1 (v2.1) modifications primarily address transition zone (TZ) interpretation. The revisions also impact peripheral zone (PZ) interpretation, which has received less attention. OBJECTIVE. The purpose of this study was to compare interobserver agreement of PI-RADS version 2 (v2) and v2.1 in the prostate PZ and TZ and perform a pilot comparison of their diagnostic performance in the two zones. METHODS. Six radiologists with varying experience retrospectively assessed 80 prostate lesions (40 PZ, 40 TZ) on MRI in separate sessions for PI-RADS v2 and v2.1. Interobserver agreement was assessed using Conger kappa (κ). For 50 lesions with pathology data, average AUC for detecting clinically significant cancer was compared between versions using multireader multicase statistical methods. Error variance and covariance results informed post hoc power analysis. RESULTS. Interobserver agreement for PI-RADS category 4 or greater was higher for version 2.1 (κ = 0.64) than version 2 (κ = 0.51) in the PZ, but similar for version 2 (κ = 0.64) and version 2.1 (κ = 0.60) in the TZ. The PI-RADS v2.1 DWI descriptor "linear/wedge-shaped" had higher agreement than its predecessor version 2 descriptor "indistinct hypointense" (κ = 0.52 vs κ = 0.18) and yielded 14 more true-negative versus five more false-negative interpretations. The ADC signal descriptor "markedly hypointense," for which only version 2.1 provides a specific definition, had lower agreement in version 2.1 (κ = 0.26) than version 2 (κ = 0.52). Modified TZ T2-weighted category 2 descriptors in version 2.1 had fair agreement (κ = 0.21), and agreement for PI-RADS category 2 in the TZ was lower in version 2.1 (κ = 0.31) than version 2 (κ = 0.57). DWI upgraded a TZ lesion category from 2 to 3 in four patients, detecting two additional cancers. Average AUC was not different between versions 2 and 2.1 for the PZ (AUC, 0.81 vs 0.85; p = .24) or the TZ (AUC, 0.69 vs 0.69; p = .94), though among experienced readers AUC was higher for version 2.1 than version 2 for the PZ (0.91 vs 0.82; p = .001). Overall performance comparison had sufficient power (0.8) to detect a 0.085 difference in AUC. CONCLUSION. Interobserver agreement improved using PI-RADS v2.1 in the PZ but not the TZ. Diagnostic performance improved using version 2.1 only in the PZ for experienced readers. Specific version 2.1 modifications yielded mixed results. CLINICAL IMPACT. The impact of PI-RADS v2.1 in the PZ is notable given the emphasis on version 2.1 TZ modifications. The findings suggest areas in which additional modification could further improve interobserver agreement and performance.

Entities:  

Keywords:  AUC; MRI; prostatic neoplasms; radiologists; reproducibility of results

Year:  2020        PMID: 32903060     DOI: 10.2214/AJR.20.24199

Source DB:  PubMed          Journal:  AJR Am J Roentgenol        ISSN: 0361-803X            Impact factor:   3.959


  9 in total

Review 1.  Diffusion and quantification of diffusion of prostate cancer.

Authors:  Yoshiko Ueno; Tsutomu Tamada; Keitaro Sofue; Takamichi Murakami
Journal:  Br J Radiol       Date:  2021-09-19       Impact factor: 3.039

2.  Quantitative Analysis of Diffusion Weighted Imaging May Improve Risk Stratification of Prostatic Transition Zone Lesions.

Authors:  Hannes Engel; Benedict Oerther; Marco Reisert; Elias Kellner; August Sigle; Christian Gratzke; Peter Bronsert; Tobias Krauss; Fabian Bamberg; Matthias Benndorf
Journal:  In Vivo       Date:  2022 Sep-Oct       Impact factor: 2.406

3.  Comparison of prostate imaging reporting and data system v2.1 and 2 in transition and peripheral zones: evaluation of interreader agreement and diagnostic performance in detecting clinically significant prostate cancer.

Authors:  Yasuyo Urase; Yoshiko Ueno; Tsutomu Tamada; Keitaro Sofue; Satoru Takahashi; Nobuyuki Hinata; Kenichi Harada; Masato Fujisawa; Takamichi Murakami
Journal:  Br J Radiol       Date:  2021-07-08       Impact factor: 3.039

4.  Comparison of diagnostic performance and inter-reader agreement between PI-RADS v2.1 and PI-RADS v2: systematic review and meta-analysis.

Authors:  Chau Hung Lee; Balamurugan Vellayappan; Cher Heng Tan
Journal:  Br J Radiol       Date:  2021-09-14       Impact factor: 3.039

5.  PI-RADS v2.1 Combined With Prostate-Specific Antigen Density for Detection of Prostate Cancer in Peripheral Zone.

Authors:  Jing Wen; Tingting Tang; Yugang Ji; Yilan Zhang
Journal:  Front Oncol       Date:  2022-04-08       Impact factor: 5.738

6.  Structured reporting in radiologic education - Potential of different PI-RADS versions in prostate MRI controlled by in-bore MR-guided biopsies.

Authors:  Marietta Garmer; Julia Karpienski; Dietrich Hw Groenemeyer; Birgit Wagener; Lars Kamper; Patrick Haage
Journal:  Br J Radiol       Date:  2021-12-16       Impact factor: 3.039

7.  Inter-reader agreement of the prostate imaging reporting and data system version v2.1 for detection of prostate cancer: A systematic review and meta-analysis.

Authors:  Jing Wen; Yugang Ji; Jing Han; Xiaocui Shen; Yi Qiu
Journal:  Front Oncol       Date:  2022-09-29       Impact factor: 5.738

8.  Bi- or multiparametric MRI in a sequential screening program for prostate cancer with PSA followed by MRI? Results from the Göteborg prostate cancer screening 2 trial.

Authors:  Jonas Wallström; Kjell Geterud; Kimia Kohestani; Stephan E Maier; Marianne Månsson; Carl-Gustaf Pihl; Andreas Socratous; Rebecka Arnsrud Godtman; Mikael Hellström; Jonas Hugosson
Journal:  Eur Radiol       Date:  2021-04-23       Impact factor: 5.315

Review 9.  [PI-RADS 2.1 and structured reporting of magnetic resonance imaging of the prostate].

Authors:  Andreas Hötker; Olivio F Donati
Journal:  Radiologe       Date:  2021-07-02       Impact factor: 0.635

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.